ELVN - Enliven Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$76.00
DETAILS
HIGH:
$82.00
LOW:
$65.00
MEDIAN:
$78.00
CONSENSUS:
$76.00
UPSIDE:
24.87%
Institutional Holders (13F)
| GURU | SHARES | VALUE | WEIGHT % | SHARES CHG | ACTION |
|---|---|---|---|---|---|
| Cooperman | 305,703 | $15.5M | 0.0% | +112,172 | INCREASED |
| Druckenmiller | 0 | $0 | -- | -- | SOLD |
| Wood | 0 | $0 | -- | -39,600 | SOLD |
Insider Trading
| DATE | INSIDER | TITLE | TYPE | SHARES | PRICE | VALUE |
|---|---|---|---|---|---|---|
| 2026-08-17 | Hohl Benjamin | officer: CHIEF FINANCIAL OFFICER | SELL | 4,630 | $58.35 | $270K |
| 2026-08-17 | Hohl Benjamin | officer: CHIEF FINANCIAL OFFICER | SELL | 1,388 | $59.35 | $82K |
| 2026-08-17 | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | SELL | 1,100 | $59.35 | $65K |
| 2026-08-17 | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | SELL | 3,900 | $58.37 | $228K |
| 2026-08-17 | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | M-Exempt | 5,000 | $2.48 | $12K |
| 2026-08-04 | Derynck Mika K | director | M-Exempt | 87,373 | $2.48 | $217K |
| 2026-08-04 | Derynck Mika K | director | SELL | 158,795 | $60.21 | $9.6M |
| 2026-08-04 | Derynck Mika K | director | M-Exempt | 27,567 | $25.28 | $697K |
| 2026-08-04 | Derynck Mika K | director | M-Exempt | 20,491 | $22.47 | $460K |
| 2026-08-04 | Derynck Mika K | director | M-Exempt | 23,364 | $14.85 | $347K |
| 2026-07-17 | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | M-Exempt | 5,000 | $2.48 | $12K |
| 2026-07-17 | Hohl Benjamin | officer: CHIEF FINANCIAL OFFICER | M-Exempt | 1,072 | $2.48 | $3K |
| 2026-07-17 | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | SELL | 231 | $50.05 | $12K |
| 2026-07-17 | Hohl Benjamin | officer: CHIEF FINANCIAL OFFICER | SELL | 123 | $53.87 | $7K |
| 2026-07-17 | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | SELL | 459 | $51.55 | $24K |
| 2026-07-17 | Hohl Benjamin | officer: CHIEF FINANCIAL OFFICER | SELL | 2,638 | $53.38 | $141K |
| 2026-07-17 | Hohl Benjamin | officer: CHIEF FINANCIAL OFFICER | SELL | 324 | $49.97 | $16K |
| 2026-07-17 | Hohl Benjamin | officer: CHIEF FINANCIAL OFFICER | SELL | 369 | $51.48 | $19K |
| 2026-07-17 | Hohl Benjamin | officer: CHIEF FINANCIAL OFFICER | SELL | 2,564 | $52.32 | $134K |
| 2026-07-17 | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | SELL | 2,063 | $52.39 | $108K |
| 2026-07-17 | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | SELL | 2,184 | $53.42 | $117K |
| 2026-07-17 | Collins Helen Louise | officer: CHIEF MEDICAL OFFICER | SELL | 63 | $53.92 | $3K |
| 2026-07-06 | Kunkel Lori Anne | director | SELL | 4,111 | $49.98 | $205K |
| 2026-07-06 | Kunkel Lori Anne | director | SELL | 5,889 | $50.84 | $299K |
| 2026-06-22 | ORBIMED ADVISORS LLC | 10 percent owner | SELL | 24,846 | $45.38 | $1.1M |